Tumor Necrosis Factor Receptor-associated Periodic Syndrome Mimicking Systemic Juvenile Idiopathic Arthritis  by Manki, Akira et al.
Tumor Necrosis Factor Receptor-
associated Periodic Syndrome
Mimicking Systemic Juvenile
Idiopathic Arthritis
Akira Manki1, Ryuta Nishikomori2, Mami Nakata-Hizume2, Taiji Kunitomi3, Syuji Takei4,
Tomoko Urakami1 and Tsuneo Morishima1
ABSTRACT
Background: We report two cases of tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
in patients in whom systemic juvenile idiopathic arthritis (JIA) had initially been diagnosed or suspected. One
patient, given a diagnosis of systemic JIA, was a 10-year-old boy who had presented with recurrent episodes of
spike-fever, skin rash, arthritis, and myalgia. The other patient was his 7-year-old sister, who presented with
similar symptoms and was suspected of having systemic JIA.
Methods: Serum levels of soluble tumor necrosis factor receptor super family 1A (TNFRSF1A), TNF-alpha, In-
terleukin (IL) -6, and C-reactive protein (CRP) were measured in two siblings and JIA patients. In addition, DNA
sequencing of the TNFRSF1A gene in two siblings was also performed.
Results: A detailed family history showed that their mother had an episode of recurrent fever, arthritis, and
myalgia with an increased serum CRP after the delivery of a daughter. Both siblings had serum levels of sol-
uble TNFRSF1A that were below the normal reference range, and that did not reach a level corresponding to
that of systemic JIA. On TNFRSF1A gene analysis, a single missense mutation resulting in C30Y was found in
both siblings.
Conclusions: Based on the clinical features and the TNFRSF1A mutation, both siblings were given a diagno-
sis of TRAPS. The serum levels of soluble TNFRSF1A, measured along with the CRP level, may be a useful
screening marker for differentiating TRAPS from systemic JIA.
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INTRODUCTION
Tumor necrosis factor receptor-associated periodic
syndrome (TRAPS) is a rare , autosomal dominant
disease that is related to mutations in the soluble
TNF receptor super family 1A (TNFRSF1A) gene.1,2
Compared with normal subjects , TRAPS patients
commonly have lower serum levels of soluble
TNFRSF1A.2-6 TRAPS is characterized by recurrent
prolonged (>1 week) attacks of fever associated with
skin rash, abdominal pain, arthralgia, and myalgia;
such episodes may respond favorably to corticoster-
oid treatment . 2,7 In contrast , systemic juvenile idi-
opathic arthritis (JIA), a disorder of unknown etiol-
ogy, is the major autoinflammatory disorder in chil-
dren. JIA patients may present with symptoms similar
to those of TRAPS, such as prolonged fever , skin
rash, and arthritis , and may also respond to corti-
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Table 1 Characteristics of systemic JIA and TRAPS
TRAPS2,11systemic JIA8-10
mutation of TNFRSF1A geneunknownetiology
yes (1―2 months) noperiodicity of atack
prolonged ( ＞ 1―week) spike-feverprolonged ( ＞ 2―week) spike-fevergeneral symptoms
skin rashskin rash
serositisserositis (pericarditis) 
localized myalgiageneralized lymphadenopathy
abdominal painenlargement of liver and spleen
conjunctivitis
periorbital edema
arthralgia (arthritis is less common) arthritisjoint symptoms
mono- or oligoarticularvariablenumber of joints involved
knee, shoulder, elbow, hip, finger, wrist, 
temporomandibular joint
variableafected joints
rare?commonjoint destruction
increased serum IL-6 and IL-8increased serum IL-1 beta, IL-6, and IL-12laboratory findings
decreased serum soluble TNFRSF1Aincreased serum soluble TNFRSF1A
increased acute phase reactants (CRP, 
serum amyloid A) 
increased acute phase reactants (CRP, 
serum amyloid A) 
costeroid treatment (Table 1).2,8-11
We present two cases of TRAPS; one was initially
diagnosed as, and the other was suspected to be sys-
temic JIA. The proper diagnosis was suggested when
we compared the patients’ serum soluble TNFRSF1A
levels, measured along with the CRP level, with those
found in systemic JIA patients.
CLINICAL SUMMARY
A 10-year-old Japanese boy was referred to our hospi-
tal because of a recurrent prolonged (about 2-week)
fever, skin rash, abdominal pain, arthritis, and myal-
gia. He had a history of repetitive episodes of these
attacks that had started at age 6 months and recurred
at intervals of 1―2 months. At 3 years of age, peri-
carditis developed. Because of the irregularity of the
recurrent attacks, his condition was misdiagnosed as
systemic JIA based on the prolonged spike-fever, skin
rash, arthritis, and pericarditis, which fulfilled the In-
ternational League of Associations for Rheumatology
(ILAR) criteria.8 Then he was started on oral predoni-
solone (about 0.9 mgkgday) and cyclosporine. The
patient’s 7-year-old sister had, at 3 years of age, also
presented with similar symptoms , including pro-
longed fever (<2 weeks), neck pain, abdominal pain,
and arthralgia. Although the clinical symptoms did
not strictly fulfill the ILAR criteria, she had also been
suspected of having systemic JIA and treated with
oral prednisolone (1 mgkgday). Furthermore, al-
though their 38-year-old mother had not had an obvi-
ous episode of periodic fever, she did have an episode
of prolonged (<1 month) elevation of C-reactive pro-
tein (CRP) accompanied only by fatigue. Moreover,
after the delivery of a daughter she had recurrent fe-
ver, arthralgia, and myalgia (Fig. 1-a). At the time of
referral to our hospital, the 10-year-old boy presented
with a low-grade fever, fatigue, and mild arthralgia in
the shoulder and knee. No skin rash, abdominal pain,
or conjunctivitis was noted. At that time, the patient
had a mild to moderate acute phase response, as indi-
cated by the WBC count (25400μl), CRP (48 mgl)
and erythrocyte sedimentation rate (68 mmhour) .
(However, at a later time when his symptoms were
not present, the acute phase response was not ob-
served . ) Other initial laboratory investigations
showed increased metalloprotease-3 (142 ngml), but
normal levels of ferritin (63.1 ngml), hyaluronic acid
(30.4 ngml), and immunoglobulin D (0.6 mgdl).
Magnetic resonance imaging with T2 enhancement
showed a synovial fluid collection without joint de-
struction in the left knee (Fig. 2). Since the patient’s
past history, family history, and the following labora-
tory findings strongly suggested the diagnosis of
TRAPS, we tapered and stopped oral prednisolone
treatment during a febrile periods, and added short-
term non-steroidal anti-inflammatory drugs during
the febrile attacks. During a febrile attack, serum lev-
els of acute-phase reactant protein, cytokines, and cy-
tokine receptors were as follows : CRP 166 mgl;
interleukin-6 (IL-6) 97.9 pgml; tumor necrosis factor-
alpha (TNF-alpha) <5 pgml; soluble TNFRSF1A
1220 pgml. During the afebrile period, CRP was 6
mgl; IL-6 was 0.9 pgml; TNF-alpha was <5 pgml;
and soluble TNFRSF1A was 378 pgml (Fig. 3). Se-
rum soluble TNFRSF1A was measured by ELISA
(Quantikine Human sTNFR1, R & D Systems Inc. ,
338 Allergology International Vol 55, No3, 2006 www.jsaweb.jp
Manki A et al.
Fig. 1 Gene analysis of family members and DNA se
quence of the TNFRSF1A gene. a Pedigree of the family. 
Patients (arow), afected (closed symbol), unafected (open 
symbol). NT no genetic analysis performed. b DNA se
quence electrophoretogram of C30Y mutation (TGT → TAT, 
indicated by arow) in TNFRSF1A which was found in both 
siblings. c DNA sequence of control donor with normal pat
tern (TGT) at position 30.
C 30Y C 30Y
NTNT G/A
a b
c
NT
NT NT
T G C T G T A C C
T G C T G T A C C
Fig. 2 Magnetic resonance imaging (T2 enhancement) of 
the 10-year-old boy shows synovial fluid colection in the 
knee joints (indicated by the arow).
Fig. 3 Measurements of soluble TNFRSF1A and CRP in 
TRAPS (closed circle), systemic JIA (open square) and nor-
mal child (open circle). Connected samples are from the 
same patients. The normal reference range of soluble 
TNFRSF1A is indicated by the shaded area.
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Minneapolis, USA) and its reference range was 749―
1966 pgml. Since the patient’s 7-year-old sister was
also suspected of having TRAPS, her oral predniso-
lone was discontinued during afebrile periods . At-
tacks of fever, abdominal pain, and arthralgia were
observed at intervals of 1 to 2 months , but disap-
peared after several days of short-term oral predniso-
lone treatment . During a febrile attack, the serum
level of soluble TNFRSF1A was 1660 pgml (CRP: 73
mgl), and while she was afebrile it was 683 pgml
(CRP: 3 mgl). Then, we investigated the serum lev-
els of soluble TNFRSF1A in systemic JIA. In our pa-
tients with systemic JIA, soluble TNFRSF1A levels
are within the normal range when serum CRP levels
are low (<50 mgl), and markedly increased (>2000
pgml) when serum CRP levels are high (>50 mgl) (
Fig. 3).
PATHOLOGICAL FINDINGS
After informed consent for the genetic analysis was
obtained from their parents, DNA sequencing of exon
1―10 in the TNFRSF1A gene was performed. In both
siblings, we found a single missense mutation, a het-
erozygous G to A transition in exon 2, which substi-
tutes a tyrosine for a cysteine at position 30 (C30Y)
(Fig. 1-b). As the same point mutation had been al-
ready reported , 12 we confirmed the diagnosis of
TRAPS. However, we could not obtain consent for se-
rological nor genetic analysis of the parents them-
selves.
DISCUSSION
In TRAPS, there are about 50 reported missense mu-
tations of the TNFSF1A gene, and many of them are
sited at cysteine residues in the extracellular domains
of TNFRSF1A. The mutation of C30Y, which was
found in our two cases, has been first reported by
Obici et al. 12,13 and shown to abrogate a disulfide
bond in the first extracellular cysteine-rich subdo-
main of TNFRSF1A. This genetic modification may
also result in defective TNFRSF1A shedding, and the
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shedding impairment of TNFRSF1A is thought to in-
duce the reduction of soluble TNFRSF1A in the se-
rum.3,5,14 Indeed, blood levels of soluble TNFRSF1A
were below the normal range both in their one case12
and our two cases. Moreover, the shedding impair-
ment may result both in persistent and increased sig-
nal transduction of TNF-alpha and in the reduction of
the capacity of soluble TNFRSF1A to catch free TNF-
alpha. This can lead to excessive and prolonged in-
flammatory cytokine production, such as IL-6, as was
seen in our cases.2,12 These cytokines can induce the
elevation of conventional inflammatory parameters
and, at the same time, may cause various physical
findings, including fever and arthritis . However , in
TRAPS including the reported case of C30Y,12 arthri-
tis associated with joint swelling and synovial fluid, as
observed in our cases, is less common than arthral-
gia.2 It has also been reported that, in systemic JIA,
serum levels of inflammatory cytokines, such as IL-1
beta, IL-6, and IL-12 are increased, and that these in-
creased levels are related to disease activity. It has
also been suggested that they would play an impor-
tant role in the associated symptoms (spike-fever, ar-
thritis, and skin rash). Of note, TNF-alpha levels in
the serum of JIA patients, even during the active pe-
riod , have been found to be comparable to those
found in normal controls and those with various other
diseases.9 However, TNF-alpha should have a role in
the pathogenesis of JIA . 10 Both of our patients
showed serum elevations of IL-6 and other acute
phase reactants during TRAPS attacks, when fever,
arthralgia, andor arthritis associated with joint swel-
ling were present ; these symptoms are commonly
seen in systemic JIA. Acute phase reactants, such as
CRP and erythrocyte sedimentation rate ( ESR ) ,
which are induced by inflammatory cytokines, were
also markedly increased during the TRAPS attacks. It
should be stressed that these clinical and laboratory
findings of TRAPS are occasionally mimicked by
those of systemic JIA, and thus it is possible to con-
fuse TRAPS with systemic JIA using conventional
screening tests.
In our cases, the two affected siblings and the his-
tory of their mother with recurrent fever and arthral-
gia did suggest TRAPS . Usually , several TRAPS
symptoms become apparent before the patient
reaches 20 years of age,2,7 but all of the mutation car-
riers did not present with typical symptoms.5,15 Since
the mother had only asymptomatic CRP elevation be-
fore the delivery of her daughter and only then pre-
sented with the suggesting symptoms, she may also
be a TRAPS patient, but a ‘silent mutation carrier’ or
‘late-onset patient’. It is not clear why there are silent
mutation carriers and such late-onset patients. Addi-
tional mutations that are associated with periodic fe-
ver syndromes have been reported to modify the
clinical symptoms or severity.16 Thus, either sibling
may have another mutation, including theMVK gene,
which may cause differences in their clinical symp-
toms.
When details of the family history became appar-
ent , we investigated the serum levels of soluble
TNFRSF1A to differentiate TRAPS from systemic JIA.
In TRAPS, soluble TNFRSF1A levels should be lower
than 1000 pgml in most patients between attacks
and remain low or increase transiently to normal val-
ues during attacks.2-5 In our two cases, both patients
showed low levels of soluble TNFRSF1A (378 ngml
and 683 ngml) between the clinical attacks that were
associated with low serum levels of CRP. However,
the levels of soluble TNFRSF1A reached normal ref-
erence levels when serum CRP levels were found to
be increased. On the other hand, in systemic JIA, the
serum levels of soluble TNFRSF1 have been reported
to be increased in the active phase and to have a posi-
tive correlation with serum CRP levels.17 Thus, per-
sistently high soluble TNFRSF1A values are thought
to be good markers of systemic JIA activity.18 How-
ever, in our two TRAPS patients, serum CRP levels
were occasionally elevated even when they were as-
ymptomatic. Thus, soluble TNFRSF1A levels should
be measured repeatedly between the attacks, even
when serum CRP levels may be increased. Accord-
ingly, CRP and other acute phase reactants should
also be measured at the same time. The measure-
ment of inflammatory cytokines and soluble
TNFRSF1A during attacks may also be useful in re-
vealing defective TNFRSF1A shedding, though TNF-
alpha and IL-6 were not always elevated in our pa-
tients when soluble TNFRSF1A was increased, which
may be due to the short half-life of these cytokines.
In conclusion, serum levels of soluble TNFRSF1A
and CRP measured at the same time can be useful in
differentiating TRAPS from systemic JIA, which can
present with similar findings.
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